Key Highlights
•
A genetic alteration called MTAP loss, found in about 15% of cancers, makes tumors more sensitive to a new class of drugs called PRMT5 inhibitors. This discovery is particularly important for lung cancers driven by specific genetic mutations, where it could open up a new, targeted treatment strategy.
Source →
•
A new study suggests that for patients with a common type of lung cancer (EGFR-mutant NSCLC), early and more intensive treatment may be beneficial, especially for those who also have mutations in tumor suppressor genes. This sharpens the approach to personalized medicine, aiming to improve outcomes by tailoring treatment based on a patient’s specific genetic profile.
Source →
•
In a type of blood cancer called myelodysplastic syndromes (MDS), researchers found that a protein called CCN2 is often overproduced, especially in a specific subtype linked to a mutation in the SF3B1 gene. This finding helps explain the disease’s biology and is significant because it points to a potential target for new therapies, including drugs that are already in clinical development.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
